Jessica Grossman, M.D., Joins Dar Bioscience Board of Directors

Jessica Grossman, M.D., Joins Dar Bioscience Board of Directors

SAN DIEGO, April 11, 2018 (GLOBE NEWSWIRE) Dar Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women s

biopharmaceutical company, today announced the appointment of Jessica Grossman, M.D., to its board of directors. Dr. Grossman is currently the CEO of Medicines360, a global nonprofit women s health pharmaceutical company that

developed the FDA-approved contraceptive IUS LILETTA (levonorgestrel-releasing intrauterine system).

We are excited to add Dr. Grossman to our highly distinguished board of directors, said Sabrina Martucci Johnson, CEO of Dar

Bioscience. Dr. Grossman brings a deep understanding of women s health along with relevant experience in product development, partnering and commercialization.

Prior to her appointment as CEO of Medicines360, Dr. Grossman served as President and Founding CEO of Sense4Baby, Inc., which developed an innovative,

wireless maternal fetal heart rate monitoring system for women with high-risk pregnancies. Dr. Grossman was also Founder and President of Gynesonics, Inc., an early-stage medical device company focused on minimally invasive solutions for

women s health, which developed the first intrauterine, ultrasound-guided radiofrequency ablation device for fibroid tumors.

join the Dar board of directors, said Dr. Grossman. I believe that Dar is at the leading edge of innovation, and I m looking forward to helping the company deliver on its mission and vision to identify and

address unmet needs in women s sexual and reproductive health.

Dr. Grossman earned a Medical Degree from Sidney Kimmel Medical College at

Thomas Jefferson University in Philadelphia and an undergraduate degree with honors from Brandeis University. In addition to her academic and professional accreditations, she has also performed research at the Beth Israel Deaconess Medical Center,

part of the Harvard Medical School system.

Medicines360, located in San Francisco, California, is a nonprofit global women s health pharmaceutical company with a mission to expand access to quality

medicines for all women regardless of their socioeconomic status, insurance coverage or geographic location. Medicines360 is committed to working with healthcare providers, advocacy groups and patients to deliver innovative and meaningful treatments

that help women around the world have greater access to the medicines they need. For more information, visit www.medicines360.org.

Dar Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for

women s reproductive health that address clear therapeutic gaps. The company is driven by a mission to identify, develop and bring to market a diverse portfolio of novel and differentiated therapies that expand treatment options, improve

outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Dar currently has two product candidates in clinical development. The first is Ovaprene , a non-hormonal monthly contraceptive ring intended to provide protection over multiple weeks between menses. The second is SST-6007 (5% Topical Sildenafil Citrate Cream), a

potential treatment for Female Sexual Arousal Disorder. SST-6007 incorporates sildenafil, the same active ingredient in Viagra , in a proprietary cream

formulation that is specifically designed to locally increase blood flow to the

vulvar-vaginal tissue in women, leading to a potential improvement in genital arousal response and overall sexual experience. Dar also has an option to enter into a license agreement for ORB-204 and ORB-214, preclinical stage injectable etonogestrel contraceptives with target 6- and

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 regarding

matters that are not historical facts, including statements relating to Dar s ability to develop Ovaprene and Topical Sildenafil at the cost and in accordance with the targeted timelines and milestones set forth herein, expectations

regarding the anticipated market demands for its products, the safety and effectiveness of its products, market acceptance of Dar s products and the qualifications and expertise of Dar s management team. Because such

statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the

initiation and completion of clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that

trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals; claims of infringement and other risks relating to Dar s owned and licensed

intellectual property rights, and other factors discussed in the Risk Factors section of Dar s Report on Form 10-K filed with the Securities and Exchange Commission on March 28,

2018. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Dar s reports to the Securities and Exchange Commission, including

Dar s reports on Forms 10-Q, 8-K and 10-K. In addition, any forward-looking statements included in this press

release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. Dar specifically disclaims any obligation to update any forward-looking statements included in

on behalf of Dar Bioscience, Inc.:

Media on behalf of Dar Bioscience, Inc.:

Canale Communications

Source: Dar Bioscience